Accueil・Liste d'Actions・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Fermé

14.88 -1.78

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

14.62

Max

14.96

Chiffres clés
By Trading Economics
Revenu	-4.3M -18M
BPA	-0.19
Employés	37
EBITDA	-5.3M -17M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+98.12% upside

Dividendes
By Acuity
Prochains Résultats	3 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	32M 1.2B
Ouverture précédente	16.66
Clôture précédente	14.88

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

15 août 2026, 23:51 UTC

U.S. Industrial Production MoM data set for August 18, 2026, amid mixed economic signals and a forecasted increase of only 0.3%.

15 août 2026, 23:51 UTC

Bitcoin is trading roughly flat during Saturday's session, remaining near the lower end of its one-month trading range and below its 20-day moving average.

15 août 2026, 23:41 UTC

U.S. equities pull back amid disappointing retail sales and consumer sentiment, while geopolitical tensions and upcoming FOMC Minutes raise concerns for market stability.

15 août 2026, 23:41 UTC

European equity and bond markets closed for holiday as U.S. consumer sentiment drops, raising concerns over economic stability ahead of key data releases.

15 août 2026, 23:41 UTC

French, Italian, and Spanish markets closed for holiday as U.S. consumer sentiment drops sharply, raising concerns over inflation and potential Federal Reserve rate hikes.

15 août 2026, 23:41 UTC

Market Complacency Amidst Bond Volatility: U.S. Stocks Slip as Consumer Sentiment Falls and Retail Sales Decline, While Crypto Shows Resilience.

15 août 2026, 23:41 UTC

Cautious Optimism for Stabilization in Canadian Housing Prices Ahead of August 20 Index Release Amid Mixed Economic Signals.

15 août 2026, 23:41 UTC

Market Analysts Brace for Philadelphia Fed Manufacturing Index Release Amid Disappointing Retail Sales and Economic Uncertainty.

15 août 2026, 23:31 UTC

China's House Price Index YoY release on August 17, 2026, shows cautious optimism as home price declines ease amid mixed economic sentiment and global investor confidence.

15 août 2026, 23:11 UTC

Cautious Market Sentiment Ahead of July 2026 Building Permits Data Release, Forecasting 1.37 Million Issued Amid Recent Volatility

15 août 2026, 23:11 UTC

Australia's Westpac Consumer Confidence Index set for release amid cautious market sentiment and global economic uncertainties.

15 août 2026, 23:01 UTC

Upcoming Housing Starts Data Release on August 18, 2026, Amid Concerns Over Consumer Spending and Inflation Impacting Real Estate Markets.

15 août 2026, 23:01 UTC

U.S. Import Prices Expected to Rise 0.1% Amid Positive Inflation Sentiment and Reduced Fed Rate Hike Expectations

15 août 2026, 23:01 UTC

U.S. Export Prices Expected to Drop 0.2% Amid Slowing Inflation and Weak Retail Sales, Influencing Fed's Interest Rate Decisions

15 août 2026, 23:01 UTC

Market Awaits U.S. Building Permits Data Amid Optimism for Construction Growth and Infrastructure Investments.

15 août 2026, 23:01 UTC

U.S. Housing Starts Data for July 2026 Set to Release on August 18, Amid Mixed Market Sentiment and Forecast of 1.35 Million Units

15 août 2026, 23:01 UTC

EUR/CAD is trading roughly flat during after-market hours, showing little change since Friday's close and remaining near the lower end of its one-month range.

15 août 2026, 22:51 UTC

Australia's Westpac Consumer Confidence Index set for August 18, 2026 release amid global economic uncertainties and mixed market performance.

15 août 2026, 22:51 UTC

Canada's July 2026 Housing Starts Data Release Expected at 248K Amid Cautious Market Sentiment and Volatile Trends.

15 août 2026, 22:51 UTC

Japan's Core Inflation Rate Expected to Rise to 1.8% YoY Amid Global Economic Pressures and Potential BoJ Interest Rate Hike

15 août 2026, 22:51 UTC

Japan's July Exports YoY Data Set for Release Amid Optimistic Market Sentiment and Strong Nikkei Performance.

15 août 2026, 22:51 UTC

Japan's July trade balance expected to show a -680 billion yen deficit amid rising import costs and weak yen, while equities gain on Wall Street optimism.

15 août 2026, 22:51 UTC

Japan's Inflation Rate Release on August 20 Expected to Impact Monetary Policy and Market Sentiment Amid Anticipated Interest Rate Hikes.

15 août 2026, 22:41 UTC

NY Empire State Manufacturing Index Set for Release Amid Caution Over Disappointing Retail Sales and Economic Sentiment.

15 août 2026, 22:41 UTC

Canada's Inflation Rate Expected to Rise 0.5% in July Amid Mixed Market Sentiments and External Economic Pressures

15 août 2026, 22:41 UTC

MBA 30-Year Mortgage Rate Release on August 19 Expected to Impact Housing Market Amid Cooling Inflation and Interest Rates

15 août 2026, 22:41 UTC

Canada's July Inflation Rate Expected to Rise from 2.8% to 3%, Amid Geopolitical Tensions and Supply Chain Disruptions

15 août 2026, 22:41 UTC

Canada's Core Inflation Rate Release on August 17, 2026, Sparks Caution Among Investors Amid Geopolitical Tensions and Trade Uncertainty.

15 août 2026, 22:41 UTC

Avalanche is trading lower today, with no specific news identified. The asset remains within its one-month range amid shifting investment patterns among younger investors.

15 août 2026, 22:32 UTC

Japan's Machinery Orders MoM data set for August 18, 2026, with a forecasted increase of 0.079%, amid positive stock market sentiment and investor confidence in capital spending.

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

98.12% hausse

Prévisions sur 12 Mois

Moyen 29.5 USD 98.12%

Haut 33 USD

Bas 27 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

Achat

Maintien

Vente

Basé sur 4 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.